<DOC>
	<DOC>NCT02358889</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).</brief_summary>
	<brief_title>Study Evaluating Intravitreal hI-con1â„¢ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Males or females of any race at least 50 years of age Active primary CNV secondary to AMD in the study eye BCVA of 70 to 24 letters (worse than 20/40 up to 20/320) in the study eye Monocular patient or patient with a BCVA of 35 or fewer letters (20/200 or worse) in the better seeing eye Any prior treatment of CNV or advanced AMD in the study eye, except for dietary supplements or vitamins Any intraocular or ocular surface surgery (including cataract surgery and laser procedures) in the study eye within 3 months Vitrectomy in the study eye Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>